Athira Pharma is a late clinical-stage biopharmaceutical company. Co.'s primary candidate, fosgonimeton (ATH-1017), is a blood brain barrier-penetrating, small molecule hepatocyte growth factor (HGF)/MET positive modulator. The primary target indication is Alzheimer's disease (AD). Co.'s product candidate for its neuropsychiatric program is ATH-1020, which is a small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and to distribute to the central nervous system. Co. has several preclinical candidates for non-AD indications, including ATH-1019, which is being developed to address peripheral indications such as peripheral neuropathy. The ATHA average annual return since 2020 is shown above.
The Average Annual Return on the ATHA average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ATHA average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ATHA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|